Benitec Biopharma Ltd (BLT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Benitec Biopharma Ltd (BLT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12400
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Benitec Biopharma Ltd (Benitec) is a clinical stage biotechnology company. The company develops novel therapeutics for the treatment of chronic and life threatening diseases based on its proprietary gene silencing DNA directed RNA interference (ddRNAi) technology. It develops ddRNAi based therapeutics for various conditions such as hepatitis B, wet age-related macular degeneration and OPMD. The company also licenses ddRNAi to various biopharmaceutical companies for the development of drugs. The company has research laboratories in Hayward, California, the US. Benitec is headquartered in Sydney, New South Wales, Australia.

Benitec Biopharma Ltd (BLT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Benitec Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Benitec Biopharma Acquires Rights to Hepbarna from Biomics 13
Partnerships 14
Axovant Sciences Enters into Research Partnership with Benitec Biopharma 14
Benitec Biopharma to Enter into Research Agreement with NantVentures 15
ReNeuron Enters into Research Agreement with Benitec Biopharma 16
Benitec Biopharma Enters Into An Agreement With Stanford University 17
Licensing Agreements 18
Axovant Sciences Enters into Licensing Agreement with Benitec Biopharma 18
Benitec Biopharma Enters into Licensing Agreement with Nant Capital 19
Benitec Biopharma Enters into Licensing Agreement with Asklepios BioPharma 20
Benitec Biopharma Enters into Option for License Agreement with Touchlight Genetics for doggybone DNA 21
Benitec Biopharma Enters into Licensing Agreement with Circuit Therapeutics 22
Benitec Biopharma Enters Into Licensing Agreement With Regen BioPharma For ddRNAi Gene Silencing Technology 23
Benitec Biopharma Enters Into Licenising Agreement With uniQure 25
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 26
Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 27
Benitec Biopharma Enters into Licensing Agreement with 4D Molecular Therapeutics 28
Benitec Biopharma Enters Into Licensing Agreement With University of New South Wales For Tribetarna 29
Equity Offering 30
Benitec Biopharma Raises USD4.7 Million in Rights Offering of Shares 30
Benitec Biopharma to Raise USD2 Million in Private Placement of American Depositary Shares 31
Benitec Biopharma Raises USD4.11 million in Private Placement of Shares 32
Benitec Biopharma Raises USD13.8 Million in Public Offering of ADS 33
Benitec Biopharma Completes Second Tranche Of Private Placement Of Shares For US$28 Million 35
Benitec Biopharma Completes Rights Offering Of Shares For US$2.7 Million 37
Benitec Biopharma Completes Private Placement Of Shares For US$7 Million 38
Benitec Biopharma Completes Second Tranche Of Private Placement Of Shares For US$7.2 Million 39
Benitec Biopharma Completes Private Placement Of Shares For US$0.2 Million 41
Benitec Biopharma Completes Private Placement Of Shares For US$0.8 Million 42
Acquisition 43
Benitec Biopharma Completes Acquisition Of Tacere Therapeutics For Up To US$1.2 Million 43
Benitec Biopharma Ltd – Key Competitors 44
Benitec Biopharma Ltd – Key Employees 45
Benitec Biopharma Ltd – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Financial Announcements 47
May 31, 2018: Benitec Biopharma reports financial results for the 2018 fiscal third quarter and provides operational update 47
May 31, 2018: Benitec Biopharma: Interim Report for the nine months ended March 31, 2018 49
Feb 22, 2018: Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update 50
Nov 29, 2017: Benitec Biopharma reports financial results for the 2018 fiscal first quarter and provides operational update 52
May 30, 2017: Benitec Biopharma : Interim Report for the nine months ended March 31, 2017 54
Corporate Communications 55
Sep 19, 2018: Benitec Biopharma names Gregory R. Reyes as senior scientific advisor 55
Oct 23, 2017: Benitec announces resignation of Director, Dr John Chiplin 56
Oct 12, 2017: Benitec announces the appointment of a new Chairman 57
Oct 10, 2017: Benitec announces resignation of Chief Business and Operations Officer 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Benitec Biopharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Benitec Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Benitec Biopharma Acquires Rights to Hepbarna from Biomics 13
Axovant Sciences Enters into Research Partnership with Benitec Biopharma 14
Benitec Biopharma to Enter into Research Agreement with NantVentures 15
ReNeuron Enters into Research Agreement with Benitec Biopharma 16
Benitec Biopharma Enters Into An Agreement With Stanford University 17
Axovant Sciences Enters into Licensing Agreement with Benitec Biopharma 18
Benitec Biopharma Enters into Licensing Agreement with Nant Capital 19
Benitec Biopharma Enters into Licensing Agreement with Asklepios BioPharma 20
Benitec Biopharma Enters into Option for License Agreement with Touchlight Genetics for doggybone DNA 21
Benitec Biopharma Enters into Licensing Agreement with Circuit Therapeutics 22
Benitec Biopharma Enters Into Licensing Agreement With Regen BioPharma For ddRNAi Gene Silencing Technology 23
Benitec Biopharma Enters Into Licenising Agreement With uniQure 25
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 26
Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 27
Benitec Biopharma Enters into Licensing Agreement with 4D Molecular Therapeutics 28
Benitec Biopharma Enters Into Licensing Agreement With University of New South Wales For Tribetarna 29
Benitec Biopharma Raises USD4.7 Million in Rights Offering of Shares 30
Benitec Biopharma to Raise USD2 Million in Private Placement of American Depositary Shares 31
Benitec Biopharma Raises USD4.11 million in Private Placement of Shares 32
Benitec Biopharma Raises USD13.8 Million in Public Offering of ADS 33
Benitec Biopharma Completes Second Tranche Of Private Placement Of Shares For US$28 Million 35
Benitec Biopharma Completes Rights Offering Of Shares For US$2.7 Million 37
Benitec Biopharma Completes Private Placement Of Shares For US$7 Million 38
Benitec Biopharma Completes Second Tranche Of Private Placement Of Shares For US$7.2 Million 39
Benitec Biopharma Completes Private Placement Of Shares For US$0.2 Million 41
Benitec Biopharma Completes Private Placement Of Shares For US$0.8 Million 42
Benitec Biopharma Completes Acquisition Of Tacere Therapeutics For Up To US$1.2 Million 43
Benitec Biopharma Ltd, Key Competitors 44
Benitec Biopharma Ltd, Key Employees 45
Benitec Biopharma Ltd, Other Locations 46
Benitec Biopharma Ltd, Subsidiaries 46

List of Figures
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Benitec Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Benitec Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Benitec Biopharma Ltd (BLT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Gezhouba Group Co Ltd (600068):企業の財務・戦略的SWOT分析
    China Gezhouba Group Co Ltd (600068) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Aegis Therapeutics LLC-製薬・医療分野:企業M&A・提携分析
    Summary Aegis Therapeutics LLC (Aegis Therapeutics) is a biotechnology company that research and develops drug delivery and drug formulation technologies. The company commercializes new drug delivery and protein stabilization technologies through product specific licenses to pharmaceutical and bioph …
  • Bel Fuse Inc. (BELFA):企業の財務・戦略的SWOT分析
    Bel Fuse Inc. (BELFA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • VWR International LLC-医療機器分野:企業M&A・提携分析
    Summary VWR International LLC (VWR), a subsidiary of VWR Corp is a medical device company that offers healthcare equipment. The company’s products comprise adhesive dispensers, adhesive labels, adhesive slides, agarose and acrylamide, air freshener dispensers, air regulation valves, aluminum foil, a …
  • Glide Pharmaceutical Technologies Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Glide Pharmaceutical Technologies Ltd (Glide Technologies), formerly Caretek Medical Ltd, is a clinical stage development company that concentrates on development and delivery of solid dose formulations of vaccines and therapeutics. Its technology portfolio includes Glide SDI, a solid dose i …
  • Catholic Health Initiatives:企業の戦略・SWOT・財務情報
    Catholic Health Initiatives - Strategy, SWOT and Corporate Finance Report Summary Catholic Health Initiatives - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • QAD Inc (QADA):企業の財務・戦略的SWOT分析
    QAD Inc (QADA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Escalon Medical Corp (ESMC):医療機器:M&Aディール及び事業提携情報
    Summary Escalon Medical Corp (Escalon) is a medical device company with primary focus on ophthalmology. It carries out the development and sale of ophthalmic medical devices. Its major products include A-Scan and B-Scan diagnostic tools, UBM high frequency/high resolution ultrasound devices, pachyme …
  • Teva Pharmaceutical Industries Ltd (TEVA)-医療機器分野:企業M&A・提携分析
    Summary Teva Pharmaceutical Industries Ltd (Teva) carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines in central nervous system (CNS), respiratory, cancer, women’s health and other therapy areas. The company off …
  • Ziehm Imaging GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Ziehm Imaging GmbH (Ziehm Imaging) is a medical device company that develops, produce and markets mobile X-ray based imaging solutions. The company's products include c-arms with flat panel detectors, c-arms with 3D imaging and c-arms with image intensifier. It offers Ziehm Vision RFD 3D, 3D …
  • ChemAxon Kft:医療機器:M&Aディール及び事業提携情報
    Summary ChemAxon Kft (ChemAxon) is a provider of software platforms. The company provides chemistry and biology software solutions and consultancy services that help in optimizing the value of chemistry information in life sciences and research and development. Its product portfolio consists of desk …
  • Great Eastern Energy Corp Ltd (GEEC):企業の財務・戦略的SWOT分析
    Summary Great Eastern Energy Corp Ltd (GEECL), a subsidiary of YKM Holdings Pvt Ltd, is an oil and gas exploration and production company. The company carries out extraction and sale of coal bed methane coalbed methane gas. It operates upstream, midstream and downstream projects in Raniganj south bl …
  • Hollysys Automation Technologies Ltd:企業の戦略・SWOT・財務分析
    Hollysys Automation Technologies Ltd - Strategy, SWOT and Corporate Finance Report Summary Hollysys Automation Technologies Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Thermedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Thermedical Inc (Thermedical) is a medical device company that develops thermal ablation therapies for various conditions. The company develops RF ablation system for treating ventricular tachycardia and similar system for treating liver cancer. It provides products such as electrosurgical g …
  • Harpoon Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Harpoon Therapeutics Inc (Harpoon Therapeutics) is a biotechnology company that offers solutions for immune-oncology diseases. The company provides products portfolio such as of HPN424, prostate specific antigen and harnesses a technology named TriTAC technology. It employs TriTAC technology …
  • Omniox Inc-製薬・医療分野:企業M&A・提携分析
    Summary Omniox Inc (Omniox) is a biotechnology company that develops new medicines for hypoxic diseases. The company's H-NOX products are tailored for the treatment of hypoxic cancers, which include giloblastoma, metastatic brain cancer, head-and-neck cancer, pancreatic cancer, lung cancer, and pros …
  • Nationwide Financial Services, Inc.:企業の戦略的SWOT分析
    Nationwide Financial Services, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • John Keells Hotels Plc:企業の戦略・SWOT・財務分析
    John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Biogen, Inc.:戦略・SWOT・企業財務分析
    Biogen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Biogen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Sihayo Gold Ltd:企業の戦略・SWOT・財務情報
    Sihayo Gold Ltd - Strategy, SWOT and Corporate Finance Report Summary Sihayo Gold Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆